Zhejiang Jolly Pharmaceutical Co.,LTD (SHE:300181)
China flag China · Delayed Price · Currency is CNY
13.56
-0.66 (-4.64%)
May 28, 2026, 3:12 PM CST

SHE:300181 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
3,1043,0312,5691,9371,7871,450
Other Revenue
9.779.778.955.218.237.26
3,1143,0412,5781,9421,8051,457
Revenue Growth (YoY)
14.10%17.96%32.71%7.61%23.86%33.60%
Cost of Revenue
1,1811,1781,019616.36534.65420.35
Gross Profit
1,9341,8631,5591,3261,2711,037
Selling, General & Admin
1,1401,090949.08874.18921.45794.25
Research & Development
66.6169.4271.9479.3864.4345.63
Other Operating Expenses
-54.64-54.55-58.7-49.99-42.32-28.31
Operating Expenses
1,1551,112968.57904.42948.8812.78
Operating Income
778.39750.52590.51421.66321.71224.26
Interest Expense
-15.79-14.44-9.29-7.62-8.32-12.07
Interest & Investment Income
3.934.7815.95224.644.41
Currency Exchange Gain (Loss)
-0-000-0-
Other Non Operating Income (Expenses)
1.81-0.23-0.470.18-0.01-1.13
EBT Excluding Unusual Items
768.35740.63596.7436.21318.02215.47
Gain (Loss) on Sale of Investments
-4-3.46-0.66-0.10.080.52
Gain (Loss) on Sale of Assets
0.580.590.350.28-9.71-1.92
Asset Writedown
-4.63-1.7-8.06-0.53--
Other Unusual Items
19.2419.618.3610.7815.748.24
Pretax Income
779.54755.67596.69446.64324.12222.31
Income Tax Expense
118.48113.2380.7355.8838.630.33
Earnings From Continuing Operations
661.06642.44515.96390.76285.52191.98
Net Income to Company
661.06642.44515.96390.76285.52191.98
Minority Interest in Earnings
-10.69-10.5-8.19-7.83-12.51-12.58
Net Income
650.37631.93507.77382.94273.01179.41
Net Income to Common
650.37631.93507.77382.94273.01179.41
Net Income Growth
19.01%24.45%32.60%40.27%52.17%102.03%
Shares Outstanding (Basic)
687687696696607619
Shares Outstanding (Diluted)
694694696696607619
Shares Change (YoY)
-0.16%-0.17%-0.10%14.76%-1.93%1.64%
EPS (Basic)
0.950.920.730.550.450.29
EPS (Diluted)
0.940.910.730.550.450.29
EPS Growth
19.19%24.66%32.73%22.22%55.17%98.77%
Free Cash Flow
355.75124.6634.16156.75140.56103.84
Free Cash Flow Per Share
0.510.180.050.230.230.17
Dividend Per Share
0.3500.3500.6000.4500.3000.200
Dividend Growth
-41.67%-41.67%33.33%50.00%50.00%100.00%
Gross Margin
62.09%61.25%60.48%68.27%70.38%71.16%
Operating Margin
25.00%24.68%22.91%21.71%17.82%15.39%
Profit Margin
20.89%20.78%19.70%19.71%15.12%12.31%
Free Cash Flow Margin
11.42%4.10%1.32%8.07%7.79%7.12%
EBITDA
854.98825.44658.75483.23378.43277.87
EBITDA Margin
27.46%27.15%25.55%24.88%20.96%19.07%
D&A For EBITDA
76.5974.9268.2461.5856.7253.61
EBIT
778.39750.52590.51421.66321.71224.26
EBIT Margin
25.00%24.68%22.91%21.71%17.82%15.39%
Effective Tax Rate
15.20%14.98%13.53%12.51%11.91%13.64%
Revenue as Reported
3,1143,0412,5781,9421,8051,457
Advertising Expenses
-736.24633.3815.71675.37528.45
Source: S&P Global Market Intelligence. Standard template. Financial Sources.